Biotech · Private company · Towson, MD, US
Amplo Biotechnology, Inc.
Track this companyFree. Adds Amplo Biotechnology, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials0None registered
Pipeline programs0None found yet
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
NIH awards4
- Targeted ColQ gene therapy for Congenital Myasthenic SyndromesFiscal year 2026 · $1.4MNIH RePORTER 5R42NS127713-04 · fetched Nov 12, 2026
- Targeted ColQ gene therapy for Congenital Myasthenic SyndromesFiscal year 2025 · $601KNIH RePORTER 4R42NS127713-03 · fetched Nov 12, 2026
- Targeted DOK7 gene therapy for Congenital Myasthenic SyndromesFiscal year 2024 · $3MNIH RePORTER 2R44NS124351-04 · fetched Nov 12, 2026
- Targeted ColQ gene therapy for Congenital Myasthenic SyndromesFiscal year 2024 · $207.1KNIH RePORTER 5R42NS127713-02 · fetched Nov 12, 2026